Pharma BD Deal Intelligence
Sumitomo Pharma America, Inc. / Foundation Medicine, Inc.
2025 · Co-Development · Complete
Foundation Medicine and Sumitomo Pharma America entered a collaboration to develop FoundationOne Heme as a companion diagnostic to identify patients with acute leukemia carrying a KMT2A rearrangement or NPM1 mutation for potential treatment with Sumitomo Pharma America's investigational menin inhibitor enzomenib (DSP-5336). Financial terms were not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Feb 18, 2025
- Deal type Co-Development
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals